Systematic and prioritised prevention
Lundbeck’s research, development and manufacturing activities are based on chemical synthesis. Consequently, we use considerable amounts of organic solvents, energy and generate waste and emissions to the air. We are managing these environmental impacts effectively and we apply an integrated approach to Health, Safety and Environment (HSE) because it helps us prioritise and motivates collaboration across our global organisation. The efforts are prioritised in our HSE Strategy and managed through an ISO14001 and OHSAS 18001 certified HSE System.
Clean processes and technology
We have the privilege of being a research-based company, which essentially means that we design the manufacturing processes from scratch. In this process, our skilled chemists are working to prevent pollution and challenge conventional ways of thinking, for instance, by substituting chemicals to minimise the impact on the environment. We also apply the continuous improvements after having established an efficient manufacturing process. An example is the recovery of used solvents that leads to lower environmental impacts and saves costs. Over the years, we have refined our skills and technical capabilities to increase the recovery of organic solvents. Currently, we are recycling more than 35% of the nine most used solvents in our chemical production. This eliminates the need for approx. 1,000 tons of solvents that saves resources for external production and transportation.
Ambitious reduction target
Climate change is one of the most significant environmental challenges to modern civilisation. Lundbeck has established a target of reducing our corporate CO2 emissions by 55% in 2020 compared to 2006. This target is recognised as ‘Science Based’ by the UN Global Compact, the World Wildlife Fund for Nature (WWF), World Resources Institute and the Carbon Disclosure Project (CDP). This means that Lundbeck’s reduction in the CO2 emission is proportional to the required global reduction that would to keep the global warming below two degrees in 2100. This is the official target of the signatories of the Paris Agreement, UN Climate Change Conference of the Parties (COP-21). We have achieved international recognition for our climate efforts by being listed on CDP's 2016 Climate A List.
Applying new knowledge
Medicines are vital in the treatment of disease in humans. However, the release of medicines into the environment can lead to adverse impacts. We aim to minimise this potential environmental impact by keeping our manufacturing processes closed and by safeguarding our distribution of finished goods. As part of obtaining marketing authorisation, we assess the environmental properties and impacts of the new medicinal products. The gained knowledge is applied to improve the design of manufacturing process and informing our patients about the safe disposal of unused medicine.
UN Global Compact Report
Each year we report on progress within our work with the ten principles of UN Global Compact.
Read and download the latest report